Repligen Corporation Stock Price and Value Analysis

Repligen Corporation (NasdaqGS:RGEN) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Repligen Corporation to reach your target.

Target type

RGEN Free Cash Flow Trend

Free Cash Flow trendline for RGEN
Free Cash Flow trendline for Repligen Corporation
CSV

Based on historical returns, we believe that Repligen Corporation can grow its free cash at a rate of about 6%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the RGEN Numbers

RGEN Price
(Repligen Corporation stock price per share)
$170.29
[?] RGEN Fair Price
(based on intrinsic value)
$32.95
[?] RGEN Safety Price (based on a variable margin of safety) $19.77
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 610% higher than other Healthcare stocks
[?] PE Ratio versus Industry 149% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 53%

Insider Activity Summary

In the six months to 2026-11-20, no insider bought shares, and 1 insider sold in 2 trades, about $186 thousand.

The six months before that had 0 buys and 3 sales.

Recent Insider Activity

Open-market buys and sells reported by Repligen Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-07-16 Garland Jason K (CFO) Sell 530 $150.00
2026-06-25 Garland Jason K (CFO) Sell 733 $145.00
2026-04-21 Loeillot Olivier (Chief Executive Officer) Sell 3,832 $140.00
2025-12-17 DAWES KAREN A Sell 275 $161.00
2025-11-25 Loeillot Olivier (Chief Executive Officer) Sell 7,041 $170.00
2025-11-18 Bylund James (Chief Operating Officer) Sell 2,191 $151.21
2025-11-13 Hunt Anthony Sell 2,500 $154.32
2025-11-13 Hunt Anthony Sell 2,923 $153.14
2025-11-13 Hunt Anthony Sell 2,100 $152.17
2025-11-13 Hunt Anthony Sell 1,784 $151.01

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,054,160 shares shorted. With 60,962,151 shares available for purchase and an average trading volume over the past 10 trading days of 913,570, it would take at least 7.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2010 730272 -3
2011 730272 2.7
2012 730272 12.6
2013 730272 24.2
2014 730272 15.9
2015 730272 12.1
2016 730272 3.8
2017 730272 12.9
2018 730272 27
2019 730272 58.9
2020 730272 50.4
2021 730272 94.2
2022 730272 131
2023 730272 68.1
2024 730272 128
2025 730272 69.9

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 13 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $783 million against net income of $584 million, or 1.34 times. Net income was negative in 3 of the 16 years, and those years are left out of the ratio.

In 2025, capital expenditures were $23.5 million, 20.0% of operating cash flow of $117 million, which leaves an estimated $93.9 million after capex. Across the 15 years with reported capex, it averaged 32.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2010 -4.1 -2.4 0.6 n/a
2011 -1.6 3.2 0.5 n/a
2012 14.2 13.4 1.3 0.95
2013 16.1 25.9 4.6 1.61
2014 8.2 18.4 5.6 2.25
2015 9.3 15.1 2.6 1.61
2016 11.7 7.5 4.3 0.64
2017 28.4 17.5 5.5 0.62
2018 16.6 32.8 10.6 1.97
2019 21.4 67.2 18.5 3.14
2020 59.9 62.6 22.5 1.05
2021 128 119 67.1 0.93
2022 186 172 84.8 0.93
2023 35.6 114 36.2 3.20
2024 -25.5 175 25.7 n/a
2025 48.9 117 23.5 2.40

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $21 million in 2010 and $738 million in 2025, a compound annual growth rate of 26.8% over 15 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 16.4% from 2024 to 2025.

Our estimated free cash flow was $69.9 million in 2025, 9.5% of revenue. In 2010 the estimated margin was negative 14.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2010 21 -3 -14.5%
2011 27.3 2.7 9.8%
2012 62.3 12.6 20.3%
2013 68.2 24.2 35.5%
2014 63.5 15.9 25.0%
2015 83.5 12.1 14.5%
2016 105 3.8 3.7%
2017 141 12.9 9.1%
2018 194 27 13.9%
2019 270 58.9 21.8%
2020 366 50.4 13.7%
2021 671 94.2 14.0%
2022 802 131 16.4%
2023 632 68.1 10.8%
2024 634 128 20.2%
2025 738 69.9 9.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $566 million against total liabilities of $844 million, or 67.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 28.6% of total assets in 2025, compared with 13.2% in 2011, an increase of 15.4 percentage points.

Stockholders equity was $2,106 million in 2025, compared with $66 million in 2011, a rise of 3091.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.1% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2011 76.1 11.2 10.1 66
2012 97 29.2 12.9 84.1
2013 119 39.8 34.5 84.1
2014 128 35.4 16.6 112
2015 146 54.1 23.5 123
2016 289 122 120 169
2017 744 174 152 592
2018 775 194 159 616
2019 1,400 528 340 1,060
2020 1,903 717 374 1,529
2021 2,358 604 608 1,750
2022 2,532 523 621 1,911
2023 2,831 751 866 1,965
2024 2,830 757 857 1,973
2025 2,950 566 844 2,106

Price Versus Our Estimated Value

Of the 16 fiscal years we can see for Repligen Corporation under its current filer, 15 show positive free cash flow.

At $170.29, the price is above our fair value estimate of $32.95 for Repligen Corporation.

Free cash flow from the first three years of data averaged $4.1 million, and from the last three $88.7 million: a sharp rise.

Year-to-year variability in free cash flow is volatile, measured at 53%.

Dividends are not in our data for Repligen Corporation.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 610% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 149% above the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Biotechnology industry, the ones closest in market capitalization to Repligen Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Repligen Corporation (RGEN) 10,886 - - - 417% above
Bio-Techne Corporation (TECH) 11,420 66.7 0.3% 1.4% 91% above
Neurocrine Biosciences (NBIX) 15,850 23.2 - - 491% above
Biogen (BIIB) 36,531 107.0 - 9.9% 69% below
Amgen (AMGN) 237,363 25.4 2.2% 4.4% 11% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 730272.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 16 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: RGEN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in RGEN

Does Repligen Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: RGEN

This example shows how we apply the Trendshare checklist to RGEN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 170.29
    • Market cap: $11B
    • EPS: -0.21
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.